The most comprehensive and go-to place for all short selling reseach reports online.
Currently a total of 275 research reports from 14 investment research firms has been aggregated, with new reports being added and updated constantly
Current Share Price: 25.640 
Blue Orca Capital
Initial Report Date(2019/02/05)Share Price:10.200  
Blue Orca is Short Corcept Therapeutics
 Details Link >
•Not only does Optime appear to be a captured specialty pharmacy, deriving most if not substantially all of its revenues from Corcept, but when we called Optime, its representative told us over a recorded phone call that Corcept and Optime were one and the same. We were then transferred to a second representative, introduced as a specialty pharmacy care coordinator, who reiterated that we had reached Corcept. We placed a recording of the call on YouTube (here) for any interested investor to listen. We believe, based on this evidence, that Corcept’s sole specialty pharmacy and exclusive distributor is an undisclosed related party. If Optime’s employees believe that Corcept and Optime are one and the same, then it creates the material risk that the Company is using its captured pharmacy to boost sales, hide losses or engage in other financial shenanigans. We can’t know for sure because Optime’s financials are not publicly available.
By wantattse 
QTsky is a question & task based crowdsourcing research platform - you can post any research need - whether it's a simple question or a complex task - and find the right industry expert or software engineer to help you obtain the right answer or solution. And you only pay on a per-question or per-task basis after your QT is completed

QTsky.com and all of its information providers will not be liable for any errors,omissions,delays or interruptions in all the information and data on the QTsky.com website or for any damages relating to your use of the information provided herein. All data,research findings,opinions and information herein, whether provided by QTsky.com or by its users,should not be treated as professional investment advice.